AstraZeneca divests Myalept to Aegerion
In order to focus on its core therapy areas, AstraZeneca PLC divested Myalept (metreleptin injection) to Aegerion Pharmaceuticals Inc., which will pay $325mm cash.
- Large Molecule
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.